Intérêt de la TEP dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1

B. Bensaïd(Hôpital d'instruction des Armées Desgenettes), P. Combemale(Centre Léon Bérard), Francesco Giammarile(International Atomic Energy Agency), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), Michel Pavic(University of Bologna)

La Revue de Médecine Interne

October 26, 2006

10.1016/j.revmed.2006.10.083

Cited by 0

Related Papers

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

|The Lancet|2019|636

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

|Neuroendocrinology|2017|495

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

|The Lancet Oncology|2015|432

Late‐Onset Combined Immune Deficiency: A Subset of Common Variable Immunodeficiency with Severe T Cell Defect

|Clinical Infectious Diseases|2009|242

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

|British Journal of Dermatology|2019|197